Prf Technologies Ltd's Comment on Sales, Marketing and Customers
The company operates under various U.S. federal and state healthcare laws and regulations that impact its clinical research, sales, marketing, and educational programs related to healthcare products and services. These laws address healthcare transactions, privacy and security of health information, anti-kickback statutes, false claims laws, civil monetary penalties, criminal laws against healthcare fraud, and reporting requirements under the Physician Payments Sunshine Act. The regulations apply to federal healthcare programs including Medicare and Medicaid, as well as commercial insurers and other third-party payors.
The pursuit of effective pain management solutions has led to innovative developments in the pharmaceutical landscape. PainReform Ltd., a clinical-stage specialty pharmaceutical company, has emerged at the forefront of this endeavor with its proprietary formulation, PRF-110, designed to address post-surgical pain, particularly following bunionectomy procedures. Recent announcements by the company indicate promising progress in the ongoing Phase 3 clinical trial of this non-opiate topical treatment, offering hope for enhanced pain management without the reliance on traditional opioid therapies. Phase 3 Trial Progress On August 20, 2024, PainReform reported encouraging early safety results from its Phase 3 bun...
PainReform, a biopharmaceutical company focused on developing innovative drug delivery systems, has announced a significant advancement in its manufacturing process for PRF-110, a product designed for pain management. The new process, which achieves an unprecedented 18-month stability for PRF-110 at room temperature, is expected to provide substantial benefits for future commercialization initiatives.Historically, pharmaceutical products often face challenges regarding stability during storage and transport, particularly those that require refrigeration or strict temperature control. The introduction of a room temperature-stable formulation addresses these challenges and enhances the logistics of drug distri...
PainReform, a pharmaceutical company specializing in pain management, has recently made significant progress in its Phase 3 clinical trials for PRF-110, a novel drug aimed at providing extended postoperative pain relief. This article will analyze three key developments: the completion of enrollment in the second part of the bunionectomy trial, the expected release of top-line data in 2024, and the successful head-to-head comparison of PRF-110 with a market-leading post-surgical analgesia.Fact 1: Completion of Enrollment in Phase 3 Bunionectomy TrialPainReform has successfully completed the enrollment process in the second part of its Phase 3 clinical trial for PRF-110 in bunionectomy patients. Building upon ...
In what is undoubtedly a significant breakthrough for PainReform Ltd, the non-opiate topical treatment of the Israel-based specialty pharmaceutical company, PRF-110, has demonstrated superior in-vitro release (IVR) rates in comparison with renowned topical post-surgical pain management products. This success corroborates the firm’s commitment to promoting non-opiate pain alleviation solutions and constitutes a transformative development in chronic pain management solutions.As a clinician-centered organization that prioritizes the reformulation of established therapeutics, PainReform has been unwavering in its mission to innovate and offer advanced pain management solutions. With the successful outcome of i...
Prf Technologies Ltd’s Comment on Sales, Marketing and Customers
The company operates under various U.S. federal and state healthcare laws and regulations that impact its clinical research, sales, marketing, and educational programs related to healthcare products and services. These laws address healthcare transactions, privacy and security of health information, anti-kickback statutes, false claims laws, civil monetary penalties, criminal laws against healthcare fraud, and reporting requirements under the Physician Payments Sunshine Act. The regulations apply to federal healthcare programs including Medicare and Medicaid, as well as commercial insurers and other third-party payors.
Sources:
Prf Technologies Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Prf Technologies Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Prf Technologies Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
411.76 %